GlassScriptPhysician profile
Donald Tecca
NPI 1235163163
$6,555.16
in general payments reported to CMS, 2019-2025
42 companies · $15.56 in 2025
The $15.56 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,802 · 2020: $1,724 · 2021: $1,418 · 2022: $1,194 · 2023: $254 · 2024: $148 · 2025: $15.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $417.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $943.26 | 2019-2023 | Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $863.01 | 2019-2023 | Breztri, Tezspire |
| Glaxosmithkline, LLC. | $763.20 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $486.09 | 2019-2022 | |
| Novo Nordisk INC | $422.43 | 2019-2023 | Ozempic, Rybelsus |
| Allergan, INC. | $272.57 | 2019-2020 | |
| Pfizer INC. | $235.85 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $216.79 | 2019-2022 | |
| Lilly USA, LLC | $212.03 | 2019-2023 | Jardiance, Emgality |
| Novartis Pharmaceuticals Corporation | $191.41 | 2019-2023 | |
| Boston Scientific Corporation | $180.54 | 2020-2023 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $169.65 | 2019-2022 | |
| Antares Pharma, INC. | $139.88 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $138.29 | 2019-2022 | |
| Astellas Pharma US INC | $121.07 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Tecca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.